Ra Capital Management LLC Has Lowered Its Tg Therapeutics INC (TGTX) Stake by $10.54 Million; Share Price Declined

Investors sentiment increased to 1.29 in 2019 Q2. Its up 0.21, from 1.08 in 2019Q1. It is positive, as 11 investors sold TGTX shares while 27 reduced holdings. 14 funds opened positions while 35 raised stakes. 41.17 million shares or 9.51% less from 45.50 million shares in 2019Q1 were reported. Alliancebernstein LP owns 110,440 shares or 0% of their US portfolio. North Star Mngmt Corporation accumulated 21,000 shares or 0.02% of the stock. Jpmorgan Chase holds 258,296 shares. Hikari has 0.05% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 50,000 shares. Charles Schwab Management holds 0% or 436,433 shares. Swiss Bancorp holds 0% or 140,500 shares in its portfolio. Tower Capital Limited Liability (Trc) stated it has 0.01% in TG Therapeutics, Inc. (NASDAQ:TGTX). Amalgamated Commercial Bank, a New York-based fund reported 13,769 shares. Forbes J M And Limited Liability Partnership accumulated 10,800 shares. Manufacturers Life Insur Com The holds 0% or 47,756 shares in its portfolio. California Employees Retirement Sys accumulated 0% or 88,500 shares. Ra Mngmt Limited Company reported 3.19% in TG Therapeutics, Inc. (NASDAQ:TGTX). Ubs Asset Mngmt Americas has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 609,374 shares. Jane Street Grp Ltd Liability Corporation holds 15,205 shares or 0% of its portfolio. 30,858 were reported by Sg Americas Securities Ltd Com.

Since June 26, 2019, it had 1 buying transaction, and 0 selling transactions for $351,750 activity.

Ra Capital Management Llc decreased its stake in Tg Therapeutics Inc (TGTX) by 16.08% based on its latest 2019Q2 regulatory filing with the SEC. Ra Capital Management Llc sold 1.32 million shares as the company’s stock declined 3.85% . The hedge fund held 6.88 million shares of the health care company at the end of 2019Q2, valued at $59.52 million, down from 8.20M at the end of the previous reported quarter. Ra Capital Management Llc who had been investing in Tg Therapeutics Inc for a number of months, seems to be less bullish one the $613.07 million market cap company. The stock decreased 4.71% or $0.32 during the last trading session, reaching $6.47. About 991,308 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has declined 31.28% since September 13, 2018 and is downtrending. It has underperformed by 31.28% the S&P500.

Analysts await TG Therapeutics, Inc. (NASDAQ:TGTX) to report earnings on November, 8. They expect $-0.37 EPS, up 13.95 % or $0.06 from last year’s $-0.43 per share. After $-0.42 actual EPS reported by TG Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -11.90 % EPS growth.

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Nasdaq.com which released: “A Big Disappointment Sends TG Therapeutics Stock Skidding 34% Today – Nasdaq” on September 25, 2018, also Finance.Yahoo.com with their article: “What Kind Of Shareholder Owns Most TG Therapeutics, Inc. (NASDAQ:TGTX) Stock? – Yahoo Finance” published on August 12, 2019, Finance.Yahoo.com published: “The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study – Yahoo Finance” on September 12, 2019. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: Streetinsider.com and their article: “TG Therapeutics (TGTX) Announces Passing of Board Member Mark Schoenebaum MD – StreetInsider.com” published on August 26, 2019 as well as Finance.Yahoo.com‘s news article titled: “Large Option Trader Sells TG Therapeutics Calls After Big Run – Yahoo Finance” with publication date: August 12, 2019.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.